Skip to main content
Erschienen in: Cardiovascular Intervention and Therapeutics 4/2020

14.01.2020 | Original Article

Confirmation of maximal hyperemia by the incremental dose of intracoronary papaverine

verfasst von: Masafumi Nakayama, Nobuhiro Tanaka, Jun Yamashita, Kiyotaka Iwasaki

Erschienen in: Cardiovascular Intervention and Therapeutics | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

We investigated the effect of the papaverine dose increment method to confirm maximal hyperemia for fractional flow reserve (FFR) measurements. We evaluated 115 consecutive patients involving 200 lesions. FFR was measured after intracoronary papaverine injection into the left (12 mg) and right (8 mg) coronary arteries as standard doses. Except for 2 patients who had ventricular tachyarrythmia (VTA), we administered a higher papaverine dose (2 mg added to the standard dose). We compared the FFR values after using different papaverine doses. VTA incidence and electrocardiogram parameters were compared according to the papaverine doses used. The QTU interval and corrected QTU were significantly prolonged after using a higher dose compared with a standard dose. VTA occurred in one patient (0.9%) at the higher dose. There was no significant difference with a strong correlation between the FFR values in the 2 doses (r = 0.963, P < 0.001). Maximal hyperemia was achieved in most patients at the standard papaverine dose. However, 19 lesions changed ischemic diagnosis at the higher dose (12 lesions changed from ischemia negative to positive, and 7 lesions changed from positive to negative). Therefore, to confirm the appropriate ischemia diagnosis for borderline FFR values, it may be favorable to perform another FFR measurement at an incremental papaverine dose.
Literatur
1.
Zurück zum Zitat Marie PY, Danchin N, Durand JF, Feldmann L, Grentzinger A, Olivier P, et al. Long-term prediction of major ischemic events by exercise thallium-201 single-photon emission computed tomography. Incremental prognostic value compared with clinical, exercise testing, catheterization and radionuclide angiographic data. J Am Coll Cardiol 1995;26: 879–886. Marie PY, Danchin N, Durand JF, Feldmann L, Grentzinger A, Olivier P, et al. Long-term prediction of major ischemic events by exercise thallium-201 single-photon emission computed tomography. Incremental prognostic value compared with clinical, exercise testing, catheterization and radionuclide angiographic data. J Am Coll Cardiol 1995;26: 879–886.
2.
Zurück zum Zitat Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007;49: 2105–2111. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007;49: 2105–2111.
3.
Zurück zum Zitat Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.CrossRef Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.CrossRef
4.
Zurück zum Zitat Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360: 213–224. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360: 213–224.
5.
Zurück zum Zitat Johnson NP, Johnson DT, Kirkeeide RL, Berry C, De Bruyne B, Fearon WF, et al. Repeatability of fractional flow reserve despite variations in systemic and coronary hemodynamics. JACC Cardiovasc Interv. 2015;8:1018–27.CrossRef Johnson NP, Johnson DT, Kirkeeide RL, Berry C, De Bruyne B, Fearon WF, et al. Repeatability of fractional flow reserve despite variations in systemic and coronary hemodynamics. JACC Cardiovasc Interv. 2015;8:1018–27.CrossRef
6.
Zurück zum Zitat Nishi T, Kitahara H, Iwata Y, Fujimoto Y, Nakayama T, Takahara M, et al. Efficacy of combined administration of intracoronary papaverine plus intravenous adenosine 5'-triphosphate in assessment of fractional flow reserve. J Cardiol. 2016;68:512–6.CrossRef Nishi T, Kitahara H, Iwata Y, Fujimoto Y, Nakayama T, Takahara M, et al. Efficacy of combined administration of intracoronary papaverine plus intravenous adenosine 5'-triphosphate in assessment of fractional flow reserve. J Cardiol. 2016;68:512–6.CrossRef
7.
Zurück zum Zitat Nakayama M, Chikamori T, Uchiyama T, Kimura Y, Hijikata N, Ito R, et al. Effects of caffeine on fractional flow reserve values measured using intravenous adenosine triphosphate. Cardiovasc Interv Ther. 2018;33:116–24.CrossRef Nakayama M, Chikamori T, Uchiyama T, Kimura Y, Hijikata N, Ito R, et al. Effects of caffeine on fractional flow reserve values measured using intravenous adenosine triphosphate. Cardiovasc Interv Ther. 2018;33:116–24.CrossRef
8.
Zurück zum Zitat Nakayama M, Tanaka N, Sakoda K, Hokama Y, Hoshino K, Kimura Y, et al. Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease. Circ J. 2015;79:530–6.CrossRef Nakayama M, Tanaka N, Sakoda K, Hokama Y, Hoshino K, Kimura Y, et al. Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease. Circ J. 2015;79:530–6.CrossRef
9.
Zurück zum Zitat Nakayama M, Saito A, Kitazawa H, Takahashi M, Sato M, Fuse K, et al. Papaverine-induced polymorphic ventricular tachycardia in relation to QTU and giant T–U waves in four cases. Intern Med. 2012;51:351–6.CrossRef Nakayama M, Saito A, Kitazawa H, Takahashi M, Sato M, Fuse K, et al. Papaverine-induced polymorphic ventricular tachycardia in relation to QTU and giant T–U waves in four cases. Intern Med. 2012;51:351–6.CrossRef
10.
Zurück zum Zitat Pijls NH. Fractional flow reserve to guide coronary revascularization. Circ J. 2013;77:561–9.CrossRef Pijls NH. Fractional flow reserve to guide coronary revascularization. Circ J. 2013;77:561–9.CrossRef
11.
Zurück zum Zitat American DA. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64–71.CrossRef American DA. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64–71.CrossRef
12.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.CrossRef Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.CrossRef
13.
Zurück zum Zitat Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version. J Atheroscler Thromb 2013;20: 733–742. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version. J Atheroscler Thromb 2013;20: 733–742.
14.
Zurück zum Zitat Pijls NH, Sels JW. Functional measurement of coronary stenosis. J Am Coll Cardiol. 2012;59:1045–57.CrossRef Pijls NH, Sels JW. Functional measurement of coronary stenosis. J Am Coll Cardiol. 2012;59:1045–57.CrossRef
15.
Zurück zum Zitat Lim WH, Koo BK, Nam CW, Doh JH, Park JJ, Yang HM, et al. Variability of fractional flow reserve according to the methods of hyperemia induction. Catheter Cardiovasc Interv. 2015;85:970–6.CrossRef Lim WH, Koo BK, Nam CW, Doh JH, Park JJ, Yang HM, et al. Variability of fractional flow reserve according to the methods of hyperemia induction. Catheter Cardiovasc Interv. 2015;85:970–6.CrossRef
16.
Zurück zum Zitat Zhang X, Shen W, Cai X, Zheng A. Polymorphous ventricular tachycardia after intracoronary papaverine: a report of 3 cases. Chin Med Sci J. 1993;8:248–9.PubMed Zhang X, Shen W, Cai X, Zheng A. Polymorphous ventricular tachycardia after intracoronary papaverine: a report of 3 cases. Chin Med Sci J. 1993;8:248–9.PubMed
17.
Zurück zum Zitat Talman CL, Winniford MD, Rossen JD, Simonetti I, Kienzle MG, Marcus ML. Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine. J Am Coll Cardiol. 1990;15:275–8.CrossRef Talman CL, Winniford MD, Rossen JD, Simonetti I, Kienzle MG, Marcus ML. Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine. J Am Coll Cardiol. 1990;15:275–8.CrossRef
18.
Zurück zum Zitat Vrolix M, Piessens J, Geest HD. Torsades de pointes after intracoronary papaverine. Eur Heart J 1991; 12: 273–276. Vrolix M, Piessens J, Geest HD. Torsades de pointes after intracoronary papaverine. Eur Heart J 1991; 12: 273–276.
19.
Zurück zum Zitat Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y. QT Prolongation and possibility of ventricular arrhythmias after intracoronary papaverine. Cardiology. 1994;84:9–13.CrossRef Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y. QT Prolongation and possibility of ventricular arrhythmias after intracoronary papaverine. Cardiology. 1994;84:9–13.CrossRef
20.
Zurück zum Zitat Jain A, Jenkins MG. Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine. Cathet Cardiovasc Diagn. 1989;18:255–7.CrossRef Jain A, Jenkins MG. Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine. Cathet Cardiovasc Diagn. 1989;18:255–7.CrossRef
21.
Zurück zum Zitat Wilson RF, White CW. Serious ventricular dysrhythmias after intracoronary papaverine. Am J Cardiol. 1988;62:1301–2.CrossRef Wilson RF, White CW. Serious ventricular dysrhythmias after intracoronary papaverine. Am J Cardiol. 1988;62:1301–2.CrossRef
22.
Zurück zum Zitat Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T. Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve. Cathet Cardiovasc Diagn. 1990;19:229–36.CrossRef Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T. Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve. Cathet Cardiovasc Diagn. 1990;19:229–36.CrossRef
23.
Zurück zum Zitat Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol. 2009;54:143–9.CrossRef Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol. 2009;54:143–9.CrossRef
24.
Zurück zum Zitat Habbab MdA, El-Sherie N. Drug-induced torsades de pointes: role of early afterdepolarizations and dispersion of repolarization. Am J Med 1990;89: 241–246. Habbab MdA, El-Sherie N. Drug-induced torsades de pointes: role of early afterdepolarizations and dispersion of repolarization. Am J Med 1990;89: 241–246.
25.
Zurück zum Zitat Shimizu W, Ohe T, Kurita T, Tokuda T, Shimomura K. Epinephrine-induced ventricular premature complexes due to early afterdepolarizations and effects of verapamil and propranolol in a patient with congenital long QT syndrome. J Cardiovasc Electrophysiol. 1994;5:438–44.CrossRef Shimizu W, Ohe T, Kurita T, Tokuda T, Shimomura K. Epinephrine-induced ventricular premature complexes due to early afterdepolarizations and effects of verapamil and propranolol in a patient with congenital long QT syndrome. J Cardiovasc Electrophysiol. 1994;5:438–44.CrossRef
26.
Zurück zum Zitat Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31:115–72.CrossRef Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31:115–72.CrossRef
27.
Zurück zum Zitat Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29:1719–26.CrossRef Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29:1719–26.CrossRef
28.
Zurück zum Zitat Yoshida H, Horie M, Otani H, Kawashima T, Onishi Y, Sasayama S. Bradycardia-induced long QT syndrome caused by a de novo missense mutation in the S2–S3 inner loop of HERG. Am J Med Genet. 2001;98:348–52.CrossRef Yoshida H, Horie M, Otani H, Kawashima T, Onishi Y, Sasayama S. Bradycardia-induced long QT syndrome caused by a de novo missense mutation in the S2–S3 inner loop of HERG. Am J Med Genet. 2001;98:348–52.CrossRef
Metadaten
Titel
Confirmation of maximal hyperemia by the incremental dose of intracoronary papaverine
verfasst von
Masafumi Nakayama
Nobuhiro Tanaka
Jun Yamashita
Kiyotaka Iwasaki
Publikationsdatum
14.01.2020
Verlag
Springer Japan
Erschienen in
Cardiovascular Intervention and Therapeutics / Ausgabe 4/2020
Print ISSN: 1868-4300
Elektronische ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-020-00641-x

Weitere Artikel der Ausgabe 4/2020

Cardiovascular Intervention and Therapeutics 4/2020 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.